Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters:: Evaluation of the sieving coefficient

被引:22
作者
Arzuaga, A.
Isla, A.
Gascon, A. R.
Maynar, J.
Corral, E.
Pedraz, J. L.
机构
[1] Univ Basque Country, Fac Pharm, Lab Pharm & Pharmaceut Technol, ES-01006 Vitoria, Spain
[2] Santiago Apostol Hosp, Intens Care Unit, Vitoria, Spain
关键词
AN69; polysulfone; piperacillin; tazobactam; sieving coefficient; saturation coefficient; continuous venovenous hemofiltration; continuous venovenous hemodialysis; continuous renal replacement therapies; protein free fraction;
D O I
10.1159/000092921
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim: Piperacillin-tazobactam is commonly used to treat infections in ICU patients. Controversial data have been published about the sieving/saturation coefficient (Sc/Sa) of piperacillin during continuous renal replacement therapies (CRRT). The objective was to evaluate the Sc/Sa of piperacillin-tazobactam during continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodialysis (CVVHD) using AN69 and polysulfone. Methods: Ringer lactate, BSA-containing Ringer lactate and plasma were circulated at 150 ml/min. The ultrafiltrate/dialysis flow was kept at 1,500 ml/min. A bolus was injected and samples were taken. Drugs were measured using HPLC. Sc/Sa was calculated according to standard formula. Results: Free passage of drugs through the membranes was reported with protein free solutions. In the presence of proteins the Sc/Sa lowered and correlated to protein free fraction. Polysulfone had a significantly higher permeability than AN69 during CVVH. Conclusion: Drug binding to albumin contributes to the decrease of the Sc/Sa of piperacillin but it does not completely justify the in vivo value obtained by some authors. Copyright (c) 2006 S. Karger AG, Basel
引用
收藏
页码:347 / 354
页数:8
相关论文
共 42 条
[1]   THE EFFECT OF PIPERACILLIN DOSE ON ELIMINATION KINETICS IN RENAL IMPAIRMENT [J].
ARONOFF, GR ;
SLOAN, RS ;
BRIER, ME ;
LUFT, FC .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (04) :543-547
[2]   Quantitation and stability of piperacillin and tazobactam in plasma and ultrafiltrate from patients undergoing continuous venovenous hemofiltration by HPLC [J].
Arzuaga, A ;
Isla, A ;
Gascón, AR ;
Maynar, J ;
Martín, A ;
Solinís, MA ;
Toral, D ;
Pedraz, JL .
BIOMEDICAL CHROMATOGRAPHY, 2005, 19 (08) :570-578
[3]   Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous Venovenous Hemofiltration [J].
Arzuaga, A ;
Maynar, J ;
Gascón, AR ;
Isla, A ;
Corral, E ;
Fonseca, F ;
Sánchez-Izquierdo, JA ;
Rello, J ;
Canut, A ;
Pedraz, JL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (02) :168-176
[4]   DRUG PRESCRIBING IN RENAL-FAILURE - DOSING GUIDELINES FOR ADULTS [J].
BENNETT, WM ;
ARONOFF, GR ;
MORRISON, G ;
GOLPER, TA ;
PULLIAM, J ;
WOLFSON, M ;
SINGER, I .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1983, 3 (03) :155-193
[5]  
BICKLEY SK, 1988, CLIN PHARMACY, V7, P198
[6]  
BRACHTENDORF T, 1994, CLIN NEPHROL, V42, pS3
[7]   CLINICAL PHARMACOKINETICS DURING CONTINUOUS HEMOFILTRATION [J].
BRESSOLLE, F ;
KINOWSKI, JM ;
DELACOUSSAYE, JE ;
WYNN, N ;
ELEDJAM, JJ ;
GALTIER, M .
CLINICAL PHARMACOKINETICS, 1994, 26 (06) :457-471
[8]   Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient's red cells [J].
Broadberry, RE ;
Farren, TW ;
Bevin, SV ;
Kohler, JA ;
Yates, S ;
Skidmore, I ;
Poole, J ;
Garratty, G .
TRANSFUSION MEDICINE, 2004, 14 (01) :53-57
[9]   Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates [J].
Brunet, S ;
Leblanc, M ;
Geadah, D ;
Parent, D ;
Courteau, S ;
Cardinal, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (03) :486-492
[10]   Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration [J].
Capellier, G ;
Cornette, C ;
Boillot, A ;
Guinchard, C ;
Jacques, T ;
Blasco, G ;
Barale, F .
CRITICAL CARE MEDICINE, 1998, 26 (01) :88-91